Literature DB >> 28295675

Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study.

Hilke Andresen-Streichert1, Yannick Beres2, Wolfgang Weinmann3, Alexandra Schröck3, Alexander Müller1, Gisela Skopp4, Sven Pischke5, Eik Vettorazzi6, Ansgar Lohse2, Björn Nashan2, Martina Sterneck5.   

Abstract

Phosphatidylethanol (PEth) is a new, highly specific alcohol marker. The aim of this study was to assess its diagnostic value in the liver transplant setting. In 51 pre- and 61 post-transplant patients with underlying alcoholic liver disease PEth, ethanol, methanol, carbohydrate-deficient transferrin (CDT), and ethyl glucuronide in urine (uEtG) and hair (hEtG) were tested and compared with patients' questionnaire reports. Twenty-eight (25%) patients tested positive for at least one alcohol marker. PEth alone revealed alcohol consumption in 18% of patients. With respect to detection of alcohol intake in the preceding week, PEth showed a 100% sensitivity. PEth testing was more sensitive than the determination of ethanol, methanol, CDT or uEtG alone [sensitivity 25% (confidence interval (CI) 95%, 7-52%), 25% (7-52%), 21% (6-45%) and 71% (41-91%), respectively], or ethanol, methanol and uEtG taken in combination with 73% (45-92%). Specificity of all markers was 92% or higher. Additional testing of hEtG revealed alcohol consumption in seven patients, not being positive for any other marker. Phosphatidylethanol was a highly specific and sensitive marker for detection of recent alcohol consumption in pre- and post-transplant patients. The additional determination of hEtG was useful in disclosing alcohol consumption 3-6 months retrospectively.
© 2017 Steunstichting ESOT.

Entities:  

Keywords:  alcoholic liver disease; carbohydrate-deficient transferrin; cirrhosis; ethyl glucuronide; methanol; phosphatidylethanol

Mesh:

Substances:

Year:  2017        PMID: 28295675     DOI: 10.1111/tri.12949

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  9 in total

1.  Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group.

Authors:  Gene Y Im; Jessica L Mellinger; Adam Winters; Elizabeth S Aby; Zurabi Lominadze; John Rice; Michael R Lucey; Juan P Arab; Aparna Goel; Loretta L Jophlin; Courtney B Sherman; Richard Parker; Po-Hung Chen; Deepika Devuni; Sandeep Sidhu; Winston Dunn; Gyongyi Szabo; Ashwani K Singal; Vijay H Shah
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-16       Impact factor: 11.382

Review 2.  Telehealth Treatment for Alcohol Misuse: Reviewing Telehealth Approaches to Increase Engagement and Reduce Risk of Alcohol-Related Hypertension.

Authors:  Dan V Blalock; Patrick S Calhoun; Matthew J Crowley; Eric A Dedert
Journal:  Curr Hypertens Rep       Date:  2019-06-17       Impact factor: 5.369

Review 3.  Alcohol Biomarkers in Clinical and Forensic Contexts.

Authors:  Hilke Andresen-Streichert; Alexander Müller; Alexander Glahn; Gisela Skopp; Martina Sterneck
Journal:  Dtsch Arztebl Int       Date:  2018-05-04       Impact factor: 5.594

4.  Phosphatidylethanol, ethyl glucuronide and ethanol in blood as complementary biomarkers for alcohol consumption.

Authors:  Jasna Neumann; Olof Beck; Michael Böttcher
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-10-05

5.  Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of Differences Between Alcohol-Related and Non-Alcohol-Related Cirrhosis Candidates.

Authors:  Jan-Paul Gundlach; Felix Braun; Finn Mötter; Alexander Bernsmeier; Pablo Barrio; Nicola Ehmke; Rainer Günther; Holger Hinrichsen; Thomas Becker; Wolfgang Weinmann; Alexandra Schröck; Michel Yegles; Friedrich Martin Wurst
Journal:  Ann Transplant       Date:  2022-06-07       Impact factor: 1.479

6.  Positive blood phosphatidylethanol concentration is associated with unfavorable waitlist-related outcomes for patients medically appropriate for liver transplantation.

Authors:  Claire S Faulkner; Collin M White; Wuttiporn Manatsathit; Bernadette Lamb; Vatsalya Vatsalya; Craig J McClain; Loretta L Jophlin
Journal:  Alcohol Clin Exp Res       Date:  2022-03-15       Impact factor: 3.928

Review 7.  Approaching Alcohol Use Disorder After Liver Transplantation for Acute Alcoholic Hepatitis.

Authors:  Peng-Sheng Ting; Ahmet Gurakar; Jason Wheatley; Geetanjali Chander; Andrew M Cameron; Po-Hung Chen
Journal:  Clin Liver Dis       Date:  2021-05-26       Impact factor: 6.265

Review 8.  Diagnostic Accuracy of Biomarkers of Alcohol Use in Patients With Liver Disease: A Systematic Review.

Authors:  Janique Arnts; Benedict T K Vanlerberghe; Sylvia Roozen; Cleo L Crunelle; Ad A M Masclee; Steven W M Olde-Damink; Ron M A Heeren; Alexander van Nuijs; Hugo Neels; Frederik Nevens; Jef Verbeek
Journal:  Alcohol Clin Exp Res       Date:  2020-12-25       Impact factor: 3.455

9.  The Role of Alcohol Biomarkers in Detecting a Physician's COVID-19-Related Acute Stress Response: A Case Report.

Authors:  Alexis G Polles; William S Jacobs; Chad Brazle; Lisa J Merlo
Journal:  J Addict Med       Date:  2022 Jan-Feb 01       Impact factor: 3.702

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.